FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, in particular to a mutant polypeptide Fc-fragment having properties of high binding affinity to FcgRIIB and having an amino acid sequence corresponding to residues from position 233 to position 332 of the Fc region of human IgG2 in accordance with EU numbering, as well as to a mutant Fc region of immunoglobulin, having properties of high binding affinity to FcgRIIB and having an amino acid sequence from position 231 to the carboxyl end of heavy chains of human IgG2 in accordance with EU numbering. Also disclosed is the use of a mutant polypeptide Fc-fragment or mutant Fc-region of immunoglobulin for constructing agonist activity of antibodies or fused proteins, an isolated polynucleotide, an expression vector, host cell, pharmaceutical composition, methods of producing mutant polypeptide Fc-fragment and mutant Fc-region of immunoglobulin and the use of the mutant polypeptide Fc-fragment and the mutant Fc-region of the immunoglobulin in the manufacture of a pharmaceutical composition having high agonist activity of the antibody or fusion protein.
EFFECT: invention has important application in optimization of antibody agonist activity.
13 cl, 17 dwg, 14 tbl, 11 ex
Title | Year | Author | Number |
---|---|---|---|
HYBRID PROTEINS OF HUMAN PROTEIN FRAGMENTS TO CREATE ORDERED MULTIMERIZED COMPOSITIONS OF IMMUNOGLOBULIN FC REGIONS WITH ENHANCED BINDING WITH A COMPLEMENT SYSTEM | 2016 |
|
RU2737378C2 |
HYBRID PROTEINS OF HUMAN PROTEIN FRAGMENTS FOR CREATING ORDERLY MULTIMERIZED COMPOSITIONS OF Fc REGIONS OF IMMUNOGLOBULINS WITH ENHANCED BINDING TO COMPLEMENT SYSTEM | 2016 |
|
RU2837284C2 |
HYBRID PROTEINS OF sPD-1-Fc VARIANT | 2019 |
|
RU2785993C2 |
MUTANT VARIANTS OF Fc IgG1 DEVOID OF EFFECTOR FUNCTIONS | 2018 |
|
RU2764559C2 |
ANTI-PCSK9 ANTIBODY, ITS ANTIGEN-BINDING DOMAIN AND MEDICAL APPLICATION THEREOF | 2016 |
|
RU2739208C2 |
ENGINEERED MULTI-SPECIFIC ANTIBODIES AND OTHER MULTIMERIC PROTEINS WITH ASYMMETRIC MUTATIONS IN THE CH2-CH3 REGION | 2018 |
|
RU2804031C2 |
Therapeutic antibodies to CD47 | 2016 |
|
RU2748401C2 |
METHOD OF PRODUCING VARIANTS OF FCYRIIB-SPECIFIC FC-REGION | 2013 |
|
RU2820161C1 |
VERSIONS OF FCΓRIIB-SPECIFIC FC-REGION | 2013 |
|
RU2729831C2 |
METHODS OF COMBINED TREATMENT OF MALIGNANT NEOPLASMS, INCLUDING AGENTS BLOCKING CTLA-4 AND PD-1 | 2020 |
|
RU2833523C2 |
Authors
Dates
2025-05-12—Published
2020-12-03—Filed